The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future

Andrew M. Evens, Martin S. Tallman, Ronald B. Gartenhaus*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

152 Scopus citations

Abstract

Arsenic trioxide (As2O3) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. The mechanism of action of As 2O3 such as differentiation and apoptosis has prompted study into combination therapy. Furthermore, the connection of the sensitivity of diseases such as APL and multiple myeloma to oxidative damage has allowed the investigation of pharmacologic modulation of the cellular redox state for potentiation of As2O3. Continued study of As 2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease.

Original languageEnglish (US)
Pages (from-to)891-900
Number of pages10
JournalLeukemia Research
Volume28
Issue number9
DOIs
StatePublished - Sep 2004

Keywords

  • Acute promyelocytic leukemia
  • Arsenic trioxide
  • Pharmacologic modulation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future'. Together they form a unique fingerprint.

Cite this